Treatment options for progressive multiple sclerosis remain the main unmet need of the field. As the understanding of multiple sclerosis (MS) pathogenesis improves, new pathways and molecules will be tested for potential reparative, remyelinating, or neuroprotective effects. The clinical outcomes used will determine successful demonstration of beneficial treatment effects to regulatory agencies, clinicians, and persons with MS. This review focuses on clinical outcome measures including the Expanded Disability Status Scale, Multiple Sclerosis Functional Composite, and novel composite measures of disability. The paper also covers cognitive outcomes and screening tests for use in clinical trials. The growing importance of patient-reported outcomes and their suitability for clinical trials is also presented. The review aims to create consensus in regard to these topics and suggestions for future research.
Introduction
One of the most significant challenges in clinical trial design for progressive multiple sclerosis (PMS) is the availability and appropriate selection of clinical outcome measures. Clinical outcomes ideally should be valid, reliable, sensitive to change in relation to the mechanism of the compound being studied, predictive of future disease evolution, easy to administer/collect, and they should also represent a meaningful effect from the perspective of persons with MS (PwMS). Measurement of worsening neurological function in a slowly progressive condition with relatively short (2-3 years) trials is inherently difficult. Clinical worsening reflects several mechanisms of injury/degeneration from a biological standpoint and also represents loss of function in several interdependent spheres. The weighting of these spheres will likely vary depending on the overall stage of the disease. For example, walking function may reflect changes in the early or middle stages of the disease but will be of little importance in those using a wheel chair continuously. The lack of appropriate outcome measures has been cited as a possible explanation for the negative clinical trial results observed in PMS. 1 In this review, we will summarize the presentation of available evidence on clinician-assessed and patient-reported outcomes (PROs).
Clinical outcome measures Expanded Disability Status Scale
The Expanded Disability Status Scale (EDSS) was developed to quantify disability and is based on a combination of the neurological exam, ambulatory capacity, and ability to carry out activities of daily living. 2 The EDSS has several advantages 3 and is accepted by regulators as a disability measurement. The EDSS is familiar to MS clinicians and allows comparison of patients on a 0-10 scale. The scale is relevant to patient function, 4 easy to obtain, and can be used in the setting of a standard neurological evaluation. However, several limitations to the EDSS have been widely discussed. 5 It is an ordinal measure, where changes between scores are not necessarily of equivalent clinical meaning. It is heavily based on the neurological exam, which is subjective and not well standardized. There is an over-reliance on lower extremity function in its mid-range; scores from 4.0 to 7.5 are solely based on ambulatory endurance and need for an assistive device. The EDSS has also shown low intra-and inter-rater reliability, 6,7 but it appears that there is better agreement in higher EDSS ranges. The EDSS also has low sensitivity to measure cognition 8 and upper limb function.
Several efforts have been made to improve the reliability of the EDSS. A first step was the creation of a more standardized version of clinical measurements with separation of different functional system scores and training procedures (Neurostatus). 9 More recently, an electronic scoring format of the Neurostatus examination, Neurostatus e-Scoring (NESC), has been used in five global multicenter studies. The NESC has the ability to provide live feedback to raters who fill out the EDSS score on an iPad® device. The use of the NESC is associated with fewer inconsistencies and errors compared to a paper worksheet. 10 The NESC was used for the recent trial of siponimod in secondary progressive multiple sclerosis (SPMS), and the 3-month confirmed disability worsening was used as the primary endpoint. 11 The study met its primary endpoint, and increased accuracy of the EDSS likely contributed to this result.
The EDSS has been used as a measure to determine worsening of disease using a threshold for change confirmed over a period of time. Due to variability in the measure and improvement in EDSS after relapses, 12 in relapsing MS, the use of 6-month confirmed worsening has been advocated. However, with more gradual worsening in progressive disease, 3-month confirmation may be sufficient. How well short-term EDSS progression predicts long-term disability remains debated. A recent analysis of a large database from clinical practice including over 16,000 PwMS and over 112,000 patient-years of follow-up indicates that using short-term confirmed changes may overestimate the long-term accumulation of disability. 13 Testing of several different criteria for disability progression showed that 12-to 24-month confirmed progression was most accurate, though may lead to fewer worsening events. Recent work using latent class modeling suggested that in primary progressive multiple sclerosis (PPMS), there may be different trajectories of worsening using the EDSS. 14 This may have an impact on patient selection for clinical trials and anticipated treatment effects.
Confirmed disability reversal of the EDSS was used as a primary outcome in a recent clinical trial of biotin in PMS. 15 Although improvement in EDSS scores has not been as well validated as EDSS worsening, it remains an attractive possible outcome for repair promoting trials.
Multiple Sclerosis Functional Composite
The Multiple Sclerosis Functional Composite (MSFC) was developed as an alternative approach to address the perceived shortcomings of the EDSS. 16 The original MSFC contained three domains including lower extremity function (timed 25-foot walk (T25FW)), upper extremity function (nine-hole peg test (9HPT)), and cognition (Paced Auditory Serial Addition Test (PASAT)). To combine the results of the component tests, Z-scores are calculated from each and averaged to form a composite score. 17 Advantages of the MSFC include increased reliability and the ability for the test to be conducted quickly by a trained technician. Psychometrically, the measurement is favorable as it yields a single continuous score from three important domains. Although practice effects can occur, these can be mitigated with baseline run-in testing. Despite these advantages and successful demonstration of a treatment effect in a large multicenter phase 3 study in SPMS, 18 regulators found problems with the use of Z-scores and how to relate it to clinically meaningful change in function. The lack of a vision measure was also considered a weakness of the original MSFC. The MSFC components may also suffer from ceiling and floor effects depending on the level of disability.
Refinement of the MSFC to establish clinical meaningfulness, increase the number of domains covered, and improve the measures', psychometric properties has been undertaken. 19 Initial recommendations called for the replacement of PASAT with the Symbol Digit Modalities Test (SDMT) and inclusion of low-contrast letter acuity (LCLA) as a vision measure. 5 The Multiple Sclerosis Outcomes and Assessments Consortium (MSOAC), an academic, industry, and regulatory partnership, was formed in 2012 with the goal of obtaining regulatory qualification of clinical trial outcome based on the MSFC approach. 20 MSOAC has reviewed the candidate measures and has proposed thresholds for meaningful changes for the T25FW, 21 9HPT, 22 LCLA, 23 and SDMT 24 (Figure 1 ). Ongoing analysis of 16 clinical trial datasets is currently underway which will allow further refinement of MSFC component tests and analysis methods. A recent example of this type of validation has been published for the T25FW using data from three large clinical trials. 25 Results demonstrated strong correlations between walking speed, change in walking speed, and PRO measures of walking function.
Other walking tests. The 6 Minute Walk Test (6MWT) is a submaximal measure of gait velocity and endurance. 26 The 6MWT correlates with disability measures and PROs (17942508). The 6MWT has good intrarater 27 and inter-rater reliability. 28 A 20% change in the 6MWT is considered clinically relevant. 29 The 6MWT has several desirable properties, as it measures endurance and not only speed, which is not captured by the T25FW. Different patterns in the 6MWT have been identified based on the level of disability and it is likely a broader test of gait function. However, the 6MWT also has a few limitations, including risk of exhaustion, risk of falls, need for a large space for walking, and floor/ceiling effects. A possible compromise is the 2 Minute Walk Test which retains some of the advantages of the 6MWT using a shorter test, but is not fully validated in MS. 30 Accelerometry and other more real-world tests of ambulation and mobility are currently being studied and probably will be applied in PMS trials with increasing frequency. 31
Composite outcome measures
The concept of combining multiple independent scales to improve the chances of observing a change is the underlying logic behind the use of composite outcomes. This should be differentiated from composite scores, which involve the analytical methods used to create a single score from several different scales. From a regulatory perspective, composite outcomes are more straight forward and have already been used in several clinical trials. Validation of composite scoring methods, including appropriate weighting of the component scores, however is more difficult and not as readily accepted by regulators. With the use of composite outcomes, there may be a risk of missing relevant domains in the composite and conversely making the measure too sensitive to change. Key concepts include using the domains additively ("and") or alternatively ("or") and whether changes need to be confirmed over some time period.
The primary endpoint of a phase 3 study of fingolimod in PPMS was a novel composite outcome measure defined as 3-month confirmed change from baseline of any of the following: (1) increase in EDSS (1 for baseline ⩽5.0 or 0.5 for baseline ⩾5.5), (2) ⩾20% increase in the T25FW, or (3) ⩾20% increase in the 9HPT. 32 Although the study failed to demonstrate efficacy, the composite outcome measure demonstrated excellent sensitivity to change with approximately 80% of subjects demonstrating confirmed worsening as defined by the composite. Post hoc analysis of data from the rituximab phase 3 study in PPMS examined a combination of different "and" "or" composite combinations of EDSS, T25FW, and 9HPT. 33 The different combinations demonstrated a beneficial treatment effect of rituximab (which was not demonstrated with EDSS alone) and treatment effects of widely differing magnitudes depending on the combination used. Interestingly, the results with changes confirmed at 12 and 24 weeks were generally comparable. Although promising, the use of specific composites may apply only very narrowly to this specific study population and results are unlikely to be generalizable.
Composite scoring can also be examined to determine no evidence of disease progression based on the different domains. When examining data from the ORATORIO trial of ocrelizumab in PPMS, a significant difference of no evidence of disease progression was found (29.1% for placebo, 42.7% for ocrelizumab). 34 However, the relative contributions of the component measures in the composite differed between the two arms. Analysis of data from a phase 3 trial of interferon beta-1a in SPMS suggested the EDSS Plus as a similar composite with the ability to distinguish SPMS subjects with active progression. 35 Currently, available data suggest that the use of composite outcome measures increases the sensitivity to detect subjects meeting the primary endpoint, but there is a risk regarding what the expected effect size will be in future studies. Defining which composite combination should be used may be difficult to predict in a given population and with given therapies and mechanisms of action.
Cognitive outcomes
Cognitive impairment is common in MS, affecting approximately 50% of patients. 36 Cognitive dysfunction in MS tends to increase in frequency with age and is more common and severe in subjects with PMS 37 compared to those with relapsing-remitting multiple sclerosis (RRMS). Cognition shows a fairly reliable association with magnetic resonance imaging (MRI) metrics including T2 and T1 lesion loads as well as white and gray matter atrophy. 38 Cognition likely reflects widespread disease processes, making it an important domain to monitor in PMS.
Cognitive batteries. Several abbreviated batteries have been proposed and are summarized in Table 1 .
The Minimal Assessment of Cognitive Function in MS (MACFIMS) was initially proposed in 2001 and subsequently validated. 39 Although the MACFIMS is comprehensive in scope, it takes over 90 minutes for completion, making it less desirable as a clinical trial outcome. More abbreviated batteries have included Rao's Brief Repeatable Battery 36 and the even more abbreviated Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). 40 The BICAMs, however, requires almost 15 minutes for testing and still may be too long in the context of a trial or clinical visit.
Quick cognitive screens. Due to the difficulties of completing an extensive cognitive battery, research has focused on the search for a single quick measure testing a domain commonly affected in MS to screen for cognitive dysfunction. The PASAT, a test of sustained attention, information processing speed, and working memory on auditory scanning, is typically completed in 5 minutes and was initially included as a test of cognition in the MSFC. It has been criticized due to prominent practice effects, 42 need for technical equipment, poor acceptance by PwMS related to the test being paced, and reliance on mathematical ability. 43 The SDMT, a test of information processing speed and working memory based on visual scanning, used in its oral version, has been identified as a quick (3 minutes) and reliable screen of cognitive function. 44 The SDMT has the advantage of being a self-paced test, without reliance on mathematical abilities, is easy to administer, and may be a better outcome measure for clinical trials. The SDMT also shows good correlations with MRI measures 45 and has been shown to be clinically meaningful. It has the ability to discriminate MS patients from controls and clinical disease courses. 39 The SDMT is a strong predictor of cognitive decline over time 46 and has been used in clinical trials showing sensitivity to treatment effects and relapses. 47 A change of 4 points on the SDMT has been proposed to be clinically meaningful (Table 1) . 24 The SDMT may also be used to screen patients for inclusion in clinical trials of agents expected to show an effect on cognition.
PROs
The growing importance of capturing the direct input of PwMS has led to the development of PROs both to validate other clinical markers and as outcomes in clinical trials. The goal of these assessments is to obtain the perspective of the patient on everyday function, neurologic disability, physical function, symptoms, psychological distress, satisfaction with treatments, and quality of life (QoL). 48 Obtaining the direct input from patient is important as PwMS and physicians do not always agree on what are the most important characteristics of disease. 49 PROs also have limitations including susceptibility to unblinding, potential "expectation bias," impact of confounders (both disease-related, for example, depression, anxiety, fatigue, cognitive impairments, comorbidities, and contextual, for example, psychosocial issues), and possible "response shift" in longitudinal assessments. 50, 51 A summary of PROs used in MS trials is presented in Table 2 .
General PROs
Several general PROs have been used to assess healthrelated QoL in MS. Some instruments were designed to capture general QoL, independent of disease state, such as the EuroQoL Five Domains 55 and the 36-Item Short Form Health Survey. 62 Measures of QoL specific to MS have been developed which attempt to capture specific dimensions important to PwMS. Many of these inventories for MS contain symptom-specific components which are weighted for a general score. The Multiple Sclerosis Impact Scale-29 (MSIS-29) 56 is probably the most widely used MS scale and has been validated in clinical trial populations. 65, 66 The MSIS-29 has been correlated with changes in the MSFC 67 71 which should be taken into account in interpreting clinical trial results.
MS symptom-specific PROs
Specific symptoms can be targeted with PROs and these will probably be important when considering therapies that may affect a specific pathway or disease manifestation in PMS. One example is a patientderived version of the EDSS, the Patient Derived Disease Steps scale, which has been used extensively in registry studies 59 and has been validated against physical measures of disability including the EDSS, 6MWT, and accelerometry. 72 Perceived walking function can be assessed with the MS Walking Scale 12, which has been extensively used in rehabilitation trials. 73 The Modified Fatigue Impact Scale (MFIS) was specifically developed for MS as a modified version of the Fatigue Impact Scale and despite wide use has some psychometric limitations. 61 Vision, an important component of MS disability can be assessed with instruments such as the National Eye Institute Visual Functioning Questionnaire, which has been used to validate LCLA measures. 74 Spasticity can be assessed on the patient-reported 0-10 spasticity Numeric Rating Scale (NRS), which has been validated and used as primary outcome measure in a phase 3 trial. 75 Tolerability to medications and monitoring of adherence can also be conducted through PRO. The Treatment Satisfaction Questionnaire for Medication has been validated in MS. 64 PROs in general will be used with increased frequency in PMS clinical trials and regulatory input on the adequacy of the measures will be key. Future work will have to focus on improving usability, validity, and interpretability. International collaboration will be needed to focus on development and validation of common tools, avoiding excessive proliferation of different measures.
Conclusion
The successful development of therapeutics in PMS will depend not only on identification of relevant pathways and effective therapies but also on outcome assessments capable of demonstrating treatment effects. The EDSS has been the measure most commonly accepted by regulatory agencies and that will be unlikely to change in the near future. However, refinements to the EDSS and combining it with other measures to create composite outcome measures may provide better sensitivity to detect change. The outcomes selected for different clinical trials will depend on the scenario and phase of testing. Studies focusing on specific mechanisms may use narrower clinical outcomes and this will include measures of both physical and cognitive disability. The importance of PROs will grow in the years to come and clinical use of these measures may help ground future clinical trials. Finally, technology-based techniques including the NESC, the Multiple Sclerosis Performance Test, MSPT, and accelerometry will play an increased role both in practice and clinical trials of PMS. valuable presentations on this topic during the workshop, as well as all the panelists for their discussion on these topics. The authors also thank Dr Carmen Tur for providing notes taken during the meeting.
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